GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (LTS:0R1D) » Definitions » Cyclically Adjusted PS Ratio

Sangamo Therapeutics (LTS:0R1D) Cyclically Adjusted PS Ratio : 0.73 (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sangamo Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-06-08), Sangamo Therapeutics's current share price is $0.5825. Sangamo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.80. Sangamo Therapeutics's Cyclically Adjusted PS Ratio for today is 0.73.

The historical rank and industry rank for Sangamo Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0R1D' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.35   Med: 17.85   Max: 69.82
Current: 0.69

During the past years, Sangamo Therapeutics's highest Cyclically Adjusted PS Ratio was 69.82. The lowest was 0.35. And the median was 17.85.

LTS:0R1D's Cyclically Adjusted PS Ratio is ranked better than
88.69% of 504 companies
in the Biotechnology industry
Industry Median: 5.47 vs LTS:0R1D: 0.69

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sangamo Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.80 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sangamo Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sangamo Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Cyclically Adjusted PS Ratio Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.92 26.02 10.79 4.13 0.65

Sangamo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 1.53 0.71 0.65 0.80

Competitive Comparison of Sangamo Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sangamo Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sangamo Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sangamo Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.5825/0.8
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sangamo Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.003/131.7762*131.7762
=0.003

Current CPI (Mar. 2024) = 131.7762.

Sangamo Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.153 100.560 0.200
201409 0.182 100.428 0.239
201412 0.218 99.070 0.290
201503 0.195 99.621 0.258
201506 0.120 100.684 0.157
201509 0.123 100.392 0.161
201512 0.130 99.792 0.172
201603 0.056 100.470 0.073
201606 0.053 101.688 0.069
201609 0.040 101.861 0.052
201612 0.126 101.863 0.163
201703 0.048 102.862 0.061
201706 0.114 103.349 0.145
201709 0.141 104.136 0.178
201712 0.154 104.011 0.195
201803 0.146 105.290 0.183
201806 0.220 106.317 0.273
201809 0.232 106.507 0.287
201812 0.262 105.998 0.326
201903 0.079 107.251 0.097
201906 0.153 108.070 0.187
201909 0.190 108.329 0.231
201912 0.473 108.420 0.575
202003 0.113 108.902 0.137
202006 0.155 108.767 0.188
202009 0.409 109.815 0.491
202012 0.182 109.897 0.218
202103 0.184 111.754 0.217
202106 0.194 114.631 0.223
202109 0.196 115.734 0.223
202112 0.192 117.630 0.215
202203 0.193 121.301 0.210
202206 0.198 125.017 0.209
202209 0.167 125.227 0.176
202212 0.165 125.222 0.174
202303 0.934 127.348 0.966
202306 0.039 128.729 0.040
202309 0.053 129.860 0.054
202312 0.011 129.419 0.011
202403 0.003 131.776 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sangamo Therapeutics  (LTS:0R1D) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sangamo Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics (LTS:0R1D) Business Description

Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Sangamo Therapeutics (LTS:0R1D) Headlines

No Headlines